DRNA - Dicerna Pharma ticks lower after Novo Nordisk withdraws antitrust filing will refile

Dicerna Pharmaceuticals (NASDAQ:DRNA) ticked lower in premarket trading after Novo Nordisk (NYSE:NVO) disclosed that its withdrew its HSR filing yesterday with the intention of refiling it tomorrow. Novo withdrew its Nov. 22 filing with U.S. antitrust regulators, according to a filing. The HSR waiting period will now expire on Dec. 24. Novo Nordisk (NVO) agreed to acquire Dicerna for more than $3B, or $38.25/share in cash, last month. Novo and Dicerna have an ongoing research collaboration to develop treatments based on ribonucleic acid interference (RNAi). Danish company expects to advance the first RNAi therapeutic from the collaboration into clinical studies in 2022. Also see SA contributor Oneil Trader's piece from last month entitled "Novo Nordisk Gets A Bargain With Dicerna Acquisition."

For further details see:

Dicerna Pharma ticks lower after Novo Nordisk withdraws antitrust filing, will refile